Non-invasive Liquid Biopsy Analysis of Epigenomics Signatures in Multiple Cancer Types
NCT03869814
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
ClearNote Health is developing a test from whole blood for the early detection of multiple cancers. The goal of this study is to employ genomics, epigenomics and proteomics methodology for the detection of cancer signal in the blood of subjects with solid tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Diagnosis of Cancer of Various Organs
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 21 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- ClearNote Health
- Last updated on ClinicalTrials.gov
- May 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- ClearNote Health, Inc. · San Diego, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.